Arcus Biosciences (RCUS) EBITDA Margin Growth (3y) (2020 - 2026)

Arcus Biosciences (RCUS) EBITDA Margin Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -1,211.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 7,794.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Arcus Biosciences 3.57 Bn 2.75 Bn - -44,424.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -44,424.00
Dec 31, 2025 -12,781.00
Sep 30, 2025 -33,403.00
Jun 30, 2025 25,056.00
Mar 31, 2025 -6,349.00
Dec 31, 2024 -47,540.00
Sep 30, 2024 60,712.00
Jun 30, 2024 53,294.00
Mar 31, 2024 75,788.00
Dec 31, 2023 -10,423.00
Sep 30, 2023 -25,241.00
Jun 30, 2023 230,665.00
Mar 31, 2023 127,886.00
Dec 31, 2022 -3,788.00
Sep 30, 2022 111,639.00
Jun 30, 2022 141,073.00
Mar 31, 2022 70,052.00
Dec 31, 2021 94,250.00
Sep 30, 2021 -54,284.00
Jun 30, 2021 46,718.00